IP Library › Granted Patent US 9,907,751
Granted Patent B2
US 9,907,751 · App. 15/358,621 · Granted Mar 6, 2018

Composition and method of use of colchicine oral liquid

Inventors: Indu Muni (North Reading, MA); Naomi Vishnupad (Reading, MA)
Assignee: RxOMEG Therapeutics LLC
A61K9/08A61K9/0053A61K31/165A61K47/10A61K47/12A61K47/24A61K47/26A61K47/36
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,907,751
App. No.
15/358,621
Granted
Mar 6, 2018
Kind
B2
Abstract

Oral liquid colchicine formulations are described herein. Methods of using the oral liquid colchicine formulations are also provided.

Claims (56)

1. A liquid solution suitable for oral administration comprising colchicine and a pharmaceutically acceptable solvent system comprised of water, buffering agents, and one or more agents selected from the group consisting of glycols, sweeteners, flavoring agents, preservatives, thickening agents, and dyes, wherein

the liquid solution is stable for 30 days to 24 months at ambient and refrigerated temperature conditions, wherein the liquid solution is comprised of the following components:

ingredient

% w/v

benzyl alcohol

 0.2-0.4%

citric acid, anhydrous

 0.1-0.3%

colchicine

0.01-1.0 mg/mL *

dibasic sodium phosphate heptahydrate

 0.8-1.6%

propylene glycol

  2-8%

glycerin

  2-10%

xanthan gum

 0.1-0.2%

water

Q.S.

*Calculated on the anhydrous, solvent free basis.

2. The liquid solution of claim 1 , wherein the pharmaceutically acceptable solvent system is comprised of one or more agents selected from the group consisting of water, propylene glycol, glycerin, benzyl alcohol, dibasic sodium phosphate heptahydrate, citric acid anhydrous, xanthan gum, sucralose, a dye, and a flavoring agent and/or taste enhancing agent.

3. The liquid solution of claim 1 , wherein the pharmaceutically acceptable solvent system is comprised of the following components:

Ingredient

% w/v

benzyl alcohol

0.3

citric acid, anhydrous

0.2

colchicine

0.012*

FD&C red no. 40

0.01

dibasic sodium phosphate heptahydrate

1.2

flavor cherry 825.662

0.125

propylene glycol

5

glycerin

5

sucralose

0.15

xanthan gum

0.15

water

Q.S.

*calculated on the anhydrous, solvent free basis.

4. The liquid colchicine solution of claim 1 , wherein the solution is stable for 3 months to 12 months at accelerated conditions.

5. The liquid colchicine solution of claim 1 , wherein the solution has a stable pH.

6. The liquid colchicine solution of claim 1 , wherein the solution has a viscosity in the range of 40-800 cps.

7. The liquid colchicine solution of claim 1 , wherein the solution is volume packaged 60 mL-473 mL.

8. The liquid colchicine solution of claim 1 , wherein the pH is range is 6.2-7.2.

9. The liquid colchicine solution of claim 1 , wherein the solution has less than 5% of total impurities.

10. The liquid colchicine solution of claim 1 , wherein the solution has less than 0.5% of degradants.

11. The liquid colchicine solution of claim 1 , wherein the degradants comprise β-lumicolchicine, γ-lumicolchicine, and/or colchiceine.

Assignments (2)
CORRECTIVE ASSIGNMENT TO CORRECT THE ASSIGNEE NAME PREVIOUSLY RECORDED AT REEL: 041341 FRAME: 0919. ASSIGNOR(S) HEREBY CONFIRMS THE ASSIGNMENT . Recorded Dec 15, 2022
From: MUNI, INDU; VISHNUPAD, NAOMI
To: RXOMEG THERAPEUTICS LLC
Reel/Frame 062134/0214 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 22, 2017
From: MUNI, INDU; VISHNUPAD, NAOMI
To: RXOMEG THERAPEUTICS, LLC
Reel/Frame 041341/0919 →
Continuity (2)
Provisional Application 62306232 · Mar 10, 2016
Related Publication 20170258715A1 · Sep 14, 2017